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Summary
 
We and others have shown that influenza A nucleoprotein (NP) targeted to the secretory path-
way cannot be processed to yield several cytotoxic T lymphocyte (CTL) epitopes in cell lines
that lack the transporter associated with antigen processing (TAP). However, a large COOH-
terminal fragment of NP is processed and presented in these cells. Full-length NP is cotransla-
tionally glycosylated in the lumen of the endoplasmic reticulum at two sites distal to the major
H2-K
 
k
 
 and H2-D
 
b
 
 restricted CTL epitopes, and we show here that pharmacological or genetic
inhibition of N-linked glycosylation, leads to the processing and presentation of both these
epitopes in a TAP-independent way.
Key words: cytotoxic T lymphocyte • antigen processing • endoplasmic reticulum • 
transporter associated with antigen processing • class I major histocompatibility complex
 
C
 
ytotoxic T lymphocytes (CTLs) recognize complexes
formed between MHC class I molecules and peptides
generally derived from the breakdown of intracellular pro-
teins. There is a large body of evidence indicating that pro-
teolysis of these proteins begins in the cytosol, probably
mediated by a multicatalytic cytosolic protease known as
the proteasome (1), and that after these initial events, pep-
tide fragments are transported into the endoplasmic reticu-
lum (ER) by the transporter associated with antigen pro-
cessing (TAP; for review see reference 2). The continued
processing or trimming of peptide epitope precursors in the
ER has been suggested by studies in which polypeptides of
up to 150 amino acids have been shown to yield nonamer
peptides in the ER of TAP-negative cell lines (3, 4). The
release of epitopes from the COOH terminus of such pre-
cursors is more efficient than from their NH
 
2
 
 termini, sug-
gesting the involvement of N-aminopeptidases (4, 5).
Other studies in which peptide epitopes were liberated
from the interior of a long polypeptide or from a protein
with an inaccessible NH
 
2
 
 terminus also suggests the in-
volvement of endoproteases in the ER (5). These activities
are insensitive to inhibitors of the proteasome, lysosomal
enzymes and calpains (3, 5).
The extent to which these proteases can act on secretory
and membrane proteins that are co-translationally inserted
into the ER is unclear. Peptides derived from glycoproteins
can be presented by class I MHC, but several of these have
been shown to be processed in the cytosol by a process of
either mistranslation (6, 7) or dislocation (8, 9), which in-
volves the retrograde translocation of glycoproteins from
the ER to the cytosol (for example see reference 10).
However, there are examples of MHC class I binding pep-
tides derived both from signal sequences and from within
secretory and membrane proteins found in association with
MHC class I molecules in TAP-negative cells (11, 12), sug-
gesting that these may be generated in the ER itself. Also,
the demonstration that other ER-targeted proteins can be
processed in a TAP-independent manner (3, 4, 13–15) sug-
gests the involvement of an alternative degradation path-
way in the ER.
One issue that has not been addressed by any of the stud-
ies looking at the processing of full-length secretory and
membrane proteins is the relationship between N-linked
glycosylation and susceptibility to antigen processing in the
ER. All the full length proteins studied thus far contained
consensus sites for attachment of N-linked glycans, and re-
gardless of other factors this could prevent their processing
and presentation from within the ER.
As a way of investigating the role of glycosylation in the
ER, we have used the observation that ER-targeted NP,
which is cotranslationally glycosylated, is not processed in
the ER to yield CTL epitopes (3, 16). Here we show that
N-glycosylations at sites distal to CTL epitopes can protect
them from processing in the ER and that the removal of
both sites is necessary before the polypeptide is susceptible
to ER processing.
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Materials and Methods
 
Cell Lines.
 
Simian COS-1 cells were grown in DMEM. Mu-
rine L cells transfected with the H-2D
 
b
 
 gene were a gift from Dr.
A. Townsend (Institute of Molecular Medicine, Oxford, UK)
and were maintained in RPMI 1640 medium. The human TAP-
negative T2 cell lines, transfected with the genes encoding H-2D
 
b
 
(T2-D
 
b
 
) or H-2K
 
k
 
 (T2-K
 
k
 
), were gifts from Dr. P. Cresswell
(Yale University, New Haven, CT) and were maintained in
RPMI 1640. LBL.174 was a gift from Dr. R. DeMars (University
of Wisconsin, Madison, WI) and was transfected with the murine
H-2 gene H-2D
 
b
 
 (0.174D
 
b
 
) by Dr. V. Cerundolo (University of
Oxford, Oxford, UK). The thymidine kinase–negative human fibro-
blast line 143 was maintained in DMEM. All media were supple-
mented with 10% FCS (Meldrum Ltd., Bourne End, UK), 50 U/ml
penicillin, 50 mg/ml streptomycin, and 2 mM 
 
l
 
-glutamine.
 
Antibodies.
 
The mAb 4.7.18 recognizes a region near the
NH
 
2
 
 terminus of influenza A nucleoprotein (NP) and was a gift
from J. Skehel (National Institute of Medical Research, Mill Hill,
UK). For immunoprecipitation studies, it was used at a final dilu-
tion of 1:100. The mAb B22.249 is specific for a conformational
epitope on the 
 
a
 
1 domain of H-2D
 
b
 
 (17) and was used for im-
munoprecipitation studies B22.949 at a final concentration of 15
 
m
 
g/ml.
 
Peptides.
 
The nonamer ASNENMDAM corresponds to resi-
dues 366–374 of NP from strain A/NT/60/68 and is the natu-
rally occurring epitope presented to CTL by H-2D
 
b
 
 (18). SDY-
ERGLI, corresponding to residues 50–57 of NP, is presented by
H-2K
 
k
 
 (19). ILKEPVHGV corresponds to residues 476–484 of
HIV pol, binds to HLA-A2, and is the naturally processed epitope
(20). All peptides were synthesized by Research Genetics, Inc.
(Huntsville, AL).
 
Site-directed Mutagenesis.
 
Oligonucleotide-directed mutagene-
sis was performed using the Muta-Gene Phagemid In Vitro Mu-
tagenesis kit (Bio-Rad Labs. Ltd., Hemel Hempstead, Hertford-
shire, UK) and single stranded pcDNA3 containing the cDNA
for wild-type NP tagged with the hemagglutinin leader sequence
(3) as a template. Single-site mutants for position 21 (NAT to
DAT) and 144 (NDT to NDA) were generated, and a further
round of mutagenesis with the reciprocal oligonucleotide was
performed to generate a gene in which both glycosylation se-
quons had been deleted. Wild-type NP (L
 
1
 
NP
 
1
 
/
 
1
 
) contains both
sites. The position 21 mutant is designated L
 
1
 
NP
 
2/1
 
, the position
144 mutant is designated L
 
1
 
NP
 
1/2
 
, and the nonglycosylated mu-
tant is designated L
 
1
 
NP
 
2/2
 
.
 
Recombinant Vaccinia Viruses.
 
Recombinant vaccinias were made
by homologous recombination into the thymidine kinase gene
using the shuttle vector pSC11.30R.2 as previously described (3).
Vaccinias encoding wild-type L
 
1
 
NP (L
 
1
 
NP
 
1
 
/
 
1
 
vacc), a nonglyco-
sylated COOH-terminal fragment of NP containing residues 368–
498 tagged with the hemagglutinin leader sequence (L
 
1
 
IMPvacc)
and influenza matrix protein (M1vacc) had been constructed pre-
viously (3, 18, 21, 22). All constructs were confirmed by dideoxy
sequencing.
 
Expression of NP Glycoforms in Mammalian Cells.
 
COS-1 cells
were transfected with 10 
 
m
 
g of sterile plasmid DNA by culturing
in 500 
 
m
 
g/ml DEAE-dextran in RPMI, followed immediately by
20 
 
m
 
l of 100-mM chloroquine. Cells were incubated at 37
 
8
 
C for
4 h, after which the transfection mix was removed and replaced
with 10% DMSO in RPMI for 3 min. This was replaced with 20 ml
of medium. Assays were performed after 48 h. For expression
from recombinant vaccinia, cells were infected at a multiplicity of
10 for 90 min at 37
 
8
 
C, after which they were washed twice, re-
suspended at 5 
 
3 
 
10
 
5
 
/ml and incubated for a total of 3 h before
 
further manipulation.
 
 
 
721.174D
 
b
 
 at 10
 
7
 
/ml were transfected by
electroporation with 50 
 
m
 
g of DNA (400 V/cm, 960 
 
m
 
F) using a
Cell Electroporator (Bio-Rad Labs., Ltd.). After 1 wk in culture,
G418-resistant cells were examined for L
 
1
 
NP expression by im-
munoprecipitation.
 
CTL Production.
 
6-wk-old
 
 
 
female C57Bl/6 (H-2
 
b
 
) and CBA
(H-2
 
k
 
) mice (Harlan Olac, Bicester, Oxfordshire, UK) were im-
munized by intraperitoneal injection of 10
 
7
 
 PFU of NP-vacc in
200 
 
m
 
l of sterile PBS. Splenocytes were prepared at day 8. Autol-
ogous, irradiated splenocytes pulsed for 1 h with 5 mM peptide
were used as stimulators. Recombinant human IL-2 was added to
the cultures at a final 10 U/ml after the third restimulation. CTL
clone F5 was a gift from A. Townsend.
 
CTL Assays.
 
Standard 4-h 
 
51
 
Cr-release assays were performed
using infected or peptide-pulsed target cells. Targets were labeled
with 
 
51
 
Cr at the time of infection for 1 h. Virus was then removed
and the cells were incubated for a further 2 h before their exposure
to CTL. Where appropriate, cells were treated with 10 
 
m
 
g/ml
tunicamycin 2 h after the start of virus infection for a further 2 h
before the 4-h killing assay. This approach was taken to ensure
that all H-2D
 
b
 
 molecules at the cell surface at the start of the kill-
ing assay had been synthesized in the presence of tunicamycin.
 
Metabolic Labeling and Immunoprecipitation.
 
This was performed
as previously described (23). 10
 
7
 
 cells labeled with 100 
 
m
 
Ci per
10
 
7
 
 cells of 
 
35
 
S Promix (Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK) for 30 min at 37
 
8
 
C were used
for each experimental point. Endoglycosidase H (Endo-H) treat-
ment of immunoprecipitates was with 1 U overnight at 37
 
8
 
C.
Immunoprecipitates were resolved on a 10% SDS-polyacrylamide
gel and analyzed by autoradiography. Comparative experiments
were exposed for the same time period. Autoradiographs were
quantitated using the BioImage Analyzer and software (Millipore
Corp., Bedford, MA) where, for pulse–chase analyses, optical
density readings were converted into a percentage value based on
the reading at the start of the chase being 100%. Where the effects
of tunicamycin were studied, the drug was added (from a stock of
1 mg/ml in DMSO) 1 h before labeling and was present at the
indicated concentration throughout the experiment. An equiva-
lent volume of DMSO was added to controls.
 
Results
 
We have previously shown that full-length NP expressed
in the ER is not processed to reveal two immunodominant
CTL epitopes in TAP-deficient cells (3, 16). One possible
reason for this is that its cotranslational glycosylation at res-
idues 21 and 144 somehow blocks antigen processing in
this compartment.
 
Blocking the Glycosylation of L
 
1
 
NP Promotes the Release of
CTL Epitopes after Processing in the ER.
 
To test this hy-
pothesis, we assessed the effect of the glycosylation inhibi-
tor tunicamycin on the ER processing of L
 
1
 
NP in T2-D
 
b
 
.
At a concentration of 10 
 
m
 
g/ml of tunicamycin, L
 
1
 
NP but
not H-2D
 
b
 
 glycosylation is substantially inhibited (data not
shown). Fig. 1 shows that, under these conditions, T2-D
 
b
 
are able to present both the D
 
b
 
-restricted epitope 366–374
(Fig. 1 
 
A
 
) and T2-K
 
k
 
 the K
 
k
 
-restricted epitope SDYEGRLI
(50-57, Fig. 1 
 
B
 
) to CTLs. In the absence of tunicamycin
treatment, no presentation occurs. Presentation of the NP
fragment L
 
1
 
IMP (which contains the D
 
b
 
-restricted but not 
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the K
 
k
 
-restricted CTL epitope) is unaffected by tunicamy-
cin treatment. In contrast to the cell lines T2-D
 
b
 
 and
T2-K
 
k
 
, the TAP-competent cell line L-D
 
b
 
 is able to
present these epitopes independently of the glycosylation
status of L
 
1
 
NP, indicating that tunicamycin exerts its effect
on the alternative, TAP-independent antigen processing
pathway. Tunicamycin treatment restores the presentation
of NP366–374 from L
 
1
 
NP in a dose-dependent manner
(Fig. 1 
 
C
 
). Thus, the presentation of NP366–374 by T2-D
 
b
 
,
induced using doses of tunicamycin that inhibit the glyco-
sylation of NP, suggests that processing of proteins within
the ER for presentation through MHC class I is directly
linked to the absence of N-linked glycans on the antigen.
The decrease in the efficiency of presentation of L
 
1
 
IMP-
derived NP366–374 by T2-D
 
b
 
 in the presence of tunica-
mycin is probably due to its effect on the level of H-2D
 
b
 
,
 
and serves to indicate that the restoration of presentation of
NP366–374 from L
 
1
 
NP
 
1
 
/
 
1
 
 that was seen in the presence
of tunicamycin is significant.
To observe the effect of deglycosylation on the ER pro-
cessing of L
 
1
 
NP in isolation of vaccinia virus infection,
presentation of the H2-D
 
b
 
–restricted epitope was investi-
gated in the TAP-negative cell line LBL721.174 transfected
with the L
 
1
 
NP gene. Fig. 2 shows that treatment of the
transfected cells with 5 
 
m
 
g/ml tunicamycin restored the
presentation of NP366–374 to CTLs to 
 
z
 
70% of that seen
when tunicamycin-treated T2-D
 
b
 
 were pulsed with 10 nM
of peptide.
To eliminate the possibility that tunicamycin restored
presentation of class I epitopes from within L
 
1
 
NP by a
mechanism separate from inhibition of antigen glycosyla-
tion, we constructed a series of mutants of L
 
1
 
NP by site-
directed mutagenesis. The asparagine at position 21 is
found in the nucleoproteins of the majority of known
strains of influenza A virus, but aspartic acid is present in
some strains. Similarly, threonine 146 is found in 
 
z
 
50% of
the known strains, with alanine present in the majority of
the remainder. We used these two naturally occurring
amino acid substitutions to remove one or both of the gly-
cosylation sequons from L
 
1
 
NP
 
1
 
/
 
1
 
. Recombinant vaccinias
encoding the three possible glycosylation variants were
then constructed. Fig. 3 shows that in contrast to infection
with L
 
1
 
NP
 
1
 
/
 
1
 
, T2-D
 
b
 
 infected with L1NP2/2vacc is able to
process and present the H2-Db–restricted epitope NP366–374
to CTLs as efficiently as from L1IMPvacc. This demon-
strates a direct correlation between the absence of N-linked
glycans and the ability to process L1NP within the ER to
yield CTL epitopes. The presence of either of the two gly-
cosylation sites alone also prevents the presentation of
NP366–374 from L1NP when expressed in T2-Db (Fig.
3). In contrast, like L1NP1/1, both are readily processed in
the cytosol of a TAP-competent cell. These results indicate
that in addition to the cytosolic processing of secretory
glycoproteins, deglycosylated glycoproteins can also be ex-
posed to TAP-independent processing pathways that are
located in a distinct compartment. The possibility that pro-
Figure 1. Tunicamycin restores presentation of two MHC class I
epitopes from NP by T2 infected with recombinant vaccinia. (A) T2-Db
(right) and L-Db (left) were infected with recombinant vaccinias as indi-
cated and incubated in the presence or absence of tunicamycin (TM) at 10
mg/ml before testing their ability to present the H2-Db–restricted epitope
ASNENMDAM to CTL clone F5. Two E/T ratios are shown: 5:1 (white
bars) and 1:1 (stippled bars). (B) The experiment was repeated with T2-Kk
(right) and L-Db ( left) to test the presentation of the H2-Kk–restricted
epitope SDYERGLI (NP50–57) to a polyclonal CTL population used at
an E/T ratio of 25:1. (C) T2-Db (right) or L-Db (left) were infected with
recombinant vaccinias as indicated and incubated in the presence or ab-
sence of tunicamycin (TM) at the doses indicated before testing their abil-
ity to present the H2-Db–restricted epitope ASNENMDAM to CTL
clone F5. Two E/T ratios are shown: 5:1 (white bars) and 1:1 (stippled bars).
Figure 2. Tunicamycin restores presentation of NP366–374 by trans-
fected 721.174Db expressing L1NP1/1. .174Db expressing L1NP1/1 (right)
(inset: expression of the transgene after pulse-labeling and immunoprecip-
itation after 3-h chase) or untransfected .174Db (left) were left untreated
(0), incubated in the presence of 5 mg/ml of tunicamycin (TM), or pulsed
with 10 nM ASNENMDAM (PEP) before testing their ability to present
the H2-Db–restricted epitope ASNENMDAM to CTL clone F5. Two
E/T ratios are shown: 5:1 (white bars) and 1:1 (stippled bars).776 Glycan-regulated Class I MHC–restricted Antigen Processing
cessing of the nonglycosylated form of NP also occurs in
the cytosol with TAP-independent transfer of the epitope
into the ER is not supported by the observation that pre-
sentation of the epitope by TAP-negative cells occurs only
if it is preceded by an ER targeting signal (3).
The Rate of L1NP Turnover Is Glycan Regulated but Does
Not Correlate with Antigen Presentation. For cytosolic pro-
cessing, there is a correlation between the rate of antigen
degradation and the efficacy with which it is presented to
CTLs. To determine whether the same correlation was
true for glycoproteins processed in the ER, we measured
the rate of degradation of all four L1NP constructs in
COS-1 cells. Fig. 4 a shows that L1NP1/1 was long-lived
with a half-life of .4 h. It remained sensitive to Endo-H
during this time (Fig. 2 and data not shown), suggesting
that it was retained in the early part of the secretory path-
way. We could not detect any secreted NP even after pro-
longed (24 h) expression (data not shown). The half-life of
NP when expressed in the ER is thus comparable to that of
NP expressed in the cytosol (21). Treatment of L1NP1/1
expressing COS-1 cells with 10 mg/ml tunicamycin (a dose
that completely inhibits glycosylation of the protein) causes
it to be degraded more rapidly with only 40% remaining
after a 4-h chase, as compared with 75% of untreated NP.
This observation was not due to a nonspecific effect of tu-
nicamycin on the cells, because L1NP2/2 is degraded with
similar kinetics to L1NP after tunicamycin treatment and is
unaffected by tunicamycin treatment. The increased rate of
degradation of deglycosylated NP appeared to be con-
trolled by the presence or absence of an N-linked glycan at
position 21. Thus, Fig. 4 b shows that, although L1NP1/2
was degraded at the same rate as L1NP1/1, L1NP2/1 was
degraded at the same rate as L1NP2/2. The slow degrada-
tion of L1NP1/2 was accelerated when it was synthesized
in the presence of tunicamycin. Since neither of the mono-
glycosylated forms are processed and presented by T2-Db,
we conclude that, unlike in the cytosol, where induction of
rapid degradation is sufficient to potentiate presentation of
class I epitopes (21), antigen processing in the ER is limited
by the presence of N-linked glycans on a protein and this
effect is independent of the degradation rate of the protein.
It is important to note that, in these experiments, the term
‘degradation’ is used operationally, since the failure to de-
tect NP by immunoprecipitation does not necessarily re-
flect its hydrolysis but could reflect other events leading to
the loss of the anti-NP mAb epitope.
Discussion
Many secretory and membrane proteins have been
shown to yield class I–restricted CTL epitopes. With re-
spect to cytosolic antigen processing, this raises a topologi-
cal paradox because these proteins are cotranslationally
transported into the ER. However, they can be exposed to
cytosolic proteases by either their mistranslation (6, 7), or
dislocation to the cytosol (8, 9). Alternatively, they can be
processed in the ER itself (3, 4, 13–15, 24).
The majority of glycoprotein antigens studied to date are
processed and presented in a TAP-dependent manner, as is
L1NP1/1 described here and elsewhere (8). Using L1NP
as a model antigen, we have shown that a controlling factor
in determining whether ER-targeted proteins can be pro-
cessed in the ER is N-glycosylation. Like the diglycosy-
lated form of the antigen (L1NP1/1), neither of the two
monoglycosylated proteins (L1NP2/1 and L1NP1/2) yielded
CTL epitopes, although they were degraded with different
kinetics. This suggested that the glycan-regulated rate of
degradation was not the controlling factor in determining
whether the protein was processed for presentation to
CTLs. Our results are consistent with the idea that a failure
to glycosylate might prohibit a nascent glycoprotein from
entering the quality control procedure that normally cul-
minates in export from the ER into either the secretory
pathway or the cytosol (where they are degraded), allowing
it to become exposed to proteases in the ER itself. The
glycosylation of proteins targeted to the secretory pathway
would therefore have the effect of preventing the genera-
tion of large numbers of class I binding peptides within the
ER by enzymes that normally function to trim peptides de-
livered by TAP. Our results show that N-glycosylation can
Figure 3. Presentation of NP366–374 to CTL clone F5 by T2-Db in-
fected with recombinant vaccinia is blocked by the presence of N-linked
glycans. T2-Db (right) and L-Db (left) were infected with recombinant vac-
cinias encoding influenza matrix protein (M1), L1IMP (IMP), L1NP1/1
(1/1), L1NP2/2 (2/2), L1NP2/1 (2/1), or L1NP1/2 (1/2), or were
pulsed with 10 nM NP366–374 (PEP) and tested for their ability to
present NP366–374 to CTL clone F5 at an E/T ratio of 5:1 (white bars) or
1:1 (stippled bars).
Figure 4. Stability of L1NP glycoforms expressed in the ER of COS-1.
The intracellular stability of (a) untreated L1NP1/1 (d), L1NP1/1 after
tunicamycin treatment (j), and L1NP2/2(m); and (b) untreated L1NP1/2
(d), L1NP1/2 after tunicamycin treatment (j), and L1NP2/1 (m) are
shown.777 Wood and Elliott Brief Definitive Report
inhibit the generation of epitopes distal to the site of glyco-
sylation, presumably by affecting the general pathway for
degradation as outlined above. By ensuring that proteins
targeted for degradation are disposed of at a site that is re-
mote from peptide delivery and trimming, the system can
ensure that under normal conditions the favored route by
which peptides interact with class I MHC molecules is via
TAP. This process may not be totally efficient since some
epitopes (25), including one in L1NP itself (16), are appar-
ently generated from glycoproteins in a TAP-independent
manner. Alternatively, some epitopes may be able to gain
entry to the ER in a TAP-independent manner, although
this is not the case for the epitopes studied here.
There are other possible immunological consequences of
this glycan-regulated antigen presentation. For example, it is
possible that some glycoprotein-derived epitopes may be
hidden from CTL surveillance through a combination of
their failure to be generated in the cytosol and the protection
afforded by N-linked oligosaccharides. The possible existence
of “hidden” epitopes within glycoproteins has implications
for the maintenance of tolerance; exposure of these
epitopes by affecting the glycosylation of the source antigen
provides a potential route for the initiation of CTL re-
sponses to novel epitopes. This could also open up the pos-
sibility of pharmacological intervention to modulate pre-
sentation of viral glycoproteins in vivo.
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